<table id="table2" stylecode="Noautorules" width="700" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2:  Clinically Significant Drug Interactions with diclofenac</caption>
<col align="right" width="20%"></col>
<col align="left" width="80%"></col>
<tbody>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="bold">Drugs That Interfere with Hemostasis</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Clinical Impact: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">
<list listtype="unordered" stylecode="Disc">
<item>Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.</item>
<item>Serotonin release by platelets plays an important role in hemostasis. Case- control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Intervention: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">Monitor patients with concomitant use of CAMBIA with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [<content stylecode="italics">see Warnings and Precautions (<linkhtml href="#MN511">5.11</linkhtml>)</content>]</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="bold">Aspirin</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Clinical Impact: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [<content stylecode="italics">see Warnings and Precautions (<linkhtml href="#MN052">5.2</linkhtml>) and Clinical Pharmacology (<linkhtml href="#MN123">12.3</linkhtml>)</content>].</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Intervention: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">Concomitant use of CAMBIA and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [<content stylecode="italics">see Warnings and Precautions (<linkhtml href="#MN511">5.11</linkhtml>)</content>].</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-blockers</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Clinical Impact: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">
<list listtype="unordered" stylecode="Disc">
<item>NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta- blockers (including propranolol).</item>
<item>In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Intervention: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">
<list listtype="unordered" stylecode="Disc">
<item>During concomitant use of CAMBIA and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.</item>
<item>During concomitant use of CAMBIA and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [<content stylecode="italics">see Warnings and Precautions (<linkhtml href="#MN056">5.6</linkhtml>)</content>].</item>
</list>
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Clinical Impact: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Intervention: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">During concomitant use of CAMBIA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [<content stylecode="italics">see Warnings and Precautions (<linkhtml href="#MN056">5.6</linkhtml>)</content>].</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Clinical Impact: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Intervention: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">During concomitant use of CAMBIA and digoxin, monitor serum digoxin levels.</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="bold">Lithium</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Clinical Impact: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Intervention: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">During concomitant use of CAMBIA and lithium, monitor patients for signs of lithium toxicity.</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="bold">Methotrexate</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Clinical Impact: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Intervention: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">During concomitant use of CAMBIA and methotrexate, monitor patients for methotrexate toxicity.</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="bold">Cyclosporine</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Clinical Impact: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">Concomitant use of CAMBIA and cyclosporine may increase cyclosporine’s nephrotoxicity.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Intervention: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">During concomitant use of CAMBIA and cyclosporine, monitor patients for signs of worsening renal function.</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="bold">NSAIDs and Salicylates</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Clinical Impact: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy  [<content stylecode="italics">see Warnings and Precautions (<linkhtml href="#MN052">5.2</linkhtml>)</content>].</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Intervention: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended.</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="bold">Pemetrexed</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Clinical Impact: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">Concomitant use of CAMBIA and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Intervention: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">
<paragraph>During concomitant use of NSAIDs and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.</paragraph>
<paragraph>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.</paragraph>
<paragraph>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="bold">Inhibitors of Cytochrome P450 2C9</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Clinical Impact: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">Diclofenac is metabolized predominantly by Cytochrome P-450 CYP2C9. Co- administration of medications that inhibit CYP2C9 may affect the pharmacokinetics of diclofenac [<content stylecode="italics">see Warnings and Precautions (<linkhtml href="#MN123">12.3</linkhtml>)</content>]</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule">
<content stylecode="italics">Intervention: </content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule">During concomitant use of CAMBIA and drugs that inhibit CYP2C9, an increase in the duration between CAMBIA doses for subsequent migraine attacks may be necessary.</td>
</tr>
</tbody>
</table>